Nucleus RadioPharma
PrivateLast Round
Corporate Funding
Apr 20, 2026
Total Funding Raised
$112M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nucleus RadioPharma operates in Healthcare & Life Sciences and is based in Rochester, Minnesota. Its latest recorded funding round was a Corporate Funding round in April 2026.
Nucleus RadioPharma is a biopharmaceutical company that operates as a contract development and manufacturing organization (CDMO) providing end-to-end supply chain and manufacturing services for targeted radiopharmaceutical therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Clinical Trials, Medical Imaging
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleus RadioPharma Comparables
Compare Nucleus RadioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AtomVie Global Radiopharma Inc. | 93% | |
| SpectronRx | 83% | |
| Isotopia Molecular Imaging | 80% |
For institutional investors. Book with your work email.
Nucleus RadioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Apr 20, 2026 | ||||
| Series A Extension | Jun 5, 2024 | ||||
| Series A | Oct 17, 2023 | ||||
| Seed | Oct 12, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nucleus RadioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Granger Management | Series A |
| OrbiMed | Corporate Funding |
| Eclipse Ventures | Seed, Series A |
| Echo Investment Capital | Series A |
| University of Missouri | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 79% MoM.
- May 20, 2026
Monthly visitors increased 86% MoM, reaching 3.4K.
For institutional investors. Book with your work email.
Nucleus RadioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nucleus RadioPharma's valuation, stock price, and market status.
Is Nucleus RadioPharma a public or private company?
Nucleus RadioPharma is a private company.
What is the current stock price of Nucleus RadioPharma?
Nucleus RadioPharma is a private company, so its shares have no public market price. Caplight tracks Nucleus RadioPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nucleus RadioPharma worth (valuation)?
Valuation information for Nucleus RadioPharma is not publicly available.
Can I buy Nucleus RadioPharma stock?
Nucleus RadioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nucleus RadioPharma's last funding round?
Nucleus RadioPharma's most recent funding round was Corporate Funding on April 20, 2026.
Who are the main investors in Nucleus RadioPharma?
Key investors in Nucleus RadioPharma include OrbiMed, Eclipse Ventures.
Will Nucleus RadioPharma IPO soon?
No public IPO plans have been announced for Nucleus RadioPharma.
How can I track Nucleus RadioPharma secondary market activity?
Caplight tracks bids, offers, and trades in Nucleus RadioPharma's shares on secondary markets.